Czaja Albert J, Carpenter Herschel A
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Dig Dis Sci. 2006 May;51(5):968-75. doi: 10.1007/s10620-006-9336-5. Epub 2006 Jun 14.
Thiopurine methyltransferase deficiency has been associated with intolerance to azathioprine. Our goals were to assess the frequency of enzyme deficiency in autoimmune hepatitis and correlate deficiency states with azathioprine intolerance. Eighty-six patients receiving azathioprine (50-150 mg daily) were evaluated for enzyme activity and azathioprine-related complications. Their findings were compared to 89 similarly treated but untested patients. Thirteen patients (15%) had low thiopurine methyltransferase levels (11.4+/- 0.9 U/ml RBC; range, 3.5-14.9 U/ml RBC). Azathioprine intolerance occurred as commonly in patients with normal or above normal enzyme levels as in patients with below normal levels (12% versus 15%, p = 0.7). Patients treated without enzyme testing had the same frequency of complications (9% versus 13%, p = 0.5) as tested patients. We conclude that routine screening of blood thiopurine methyltransferase levels has a low yield for identifying individual patients at risk for azathioprine toxicity during conventional low dose therapy for autoimmune hepatitis.
硫嘌呤甲基转移酶缺乏与对硫唑嘌呤不耐受有关。我们的目标是评估自身免疫性肝炎中酶缺乏的频率,并将缺乏状态与硫唑嘌呤不耐受相关联。对86例接受硫唑嘌呤(每日50 - 150毫克)治疗的患者进行了酶活性及硫唑嘌呤相关并发症评估。将他们的结果与89例接受类似治疗但未进行检测的患者进行比较。13例患者(15%)硫嘌呤甲基转移酶水平较低(红细胞中为11.4±0.9 U/ml;范围为3.5 - 14.9 U/ml红细胞)。酶水平正常或高于正常的患者中硫唑嘌呤不耐受的发生率与低于正常水平的患者相同(分别为12%和15%,p = 0.7)。未进行酶检测而接受治疗的患者与进行检测的患者并发症发生率相同(分别为9%和13%,p = 0.5)。我们得出结论,在自身免疫性肝炎的常规低剂量治疗期间,常规筛查血液硫嘌呤甲基转移酶水平对于识别有硫唑嘌呤毒性风险的个体患者的收益较低。